IMYX 3
Alternative Names: IMYX-3; IMYX-3 COPD; IMYX-3 IBDLatest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator Immunyx
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Neutrophil modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease; Inflammatory bowel diseases
Most Recent Events
- 28 Aug 2024 Immunyx plans pre-IND evaluation for Chronic obstructive pulmonary disease in the third quarter of 2024 (Immunyx pipeline, August 2024)
- 05 Jun 2024 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route), prior to June 2024 (Immunyx pipeline, June 2024)
- 02 Feb 2023 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified) (Immunyx pipeline; January 2023)